Mood and affect during detoxification of opiate addicts: A comparison of buprenorphine versus methadone

Addiction Biology

Volumn 10, Issue 2, 2005, Pages 157-164

  Seifert, J ^a   Metzner, C ^a   Paetzold, W ^a   Borsutzky, M ^a   Ohlmeier, M ^a   Passie, T ^a   Hauser, U ^a   Becker, H ^a   Wiese, B ^a   Emrich, H M ^a   Schneider, U ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CANNABIS; CARBAMAZEPINE; COCAINE; ETIRACETAM; GABAPENTIN; METHADONE; OPIATE; PSYCHEDELIC AGENT; TETRAHYDROCANNABINOL; VIGABATRIN;

ADULT; AFFECT; AGGRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DETOXIFICATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG MISUSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INSOMNIA; LOW DRUG DOSE; MALE; MOOD DISORDER; MULTIPLE DRUG ABUSE; OPIATE ADDICTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; ANTICONVULSANTS; BUPRENORPHINE; CARBAMAZEPINE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; METHADONE; MOOD DISORDERS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS;

EID: 22144435902     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1080/13556210500123191     Document Type: Article

References (66)

1. Amass L, Bickel WK, Higgins ST, Hughes JR. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis 1994;13:33-45.
2. Amato L, Davoli M, Ferri M, Gowing L, Perucci CA. Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug Alcohol Depend 2004;73:219-226.
3. Banys P, Clark HW, Tusel DJ et al. An open trial of low dose buprenorphine in treating methadone withdrawal. J Subst Abuse Treat 1994;11:9-15.
4. Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 2000;14:301-19.
5. Bouchez J, Beauverie P, Touzeau D. Substitution with buprenorphine in methadone- and morphine sulfate-dependent patients. Preliminary results. Eur Addict Res 1998;4 (Suppl 1):8-12.
6. Bradley BP, Phillips G, Green L, Gossop M. Circumstances surrounding the initial lapse to opiate use following detoxification. Br J Psychiatry 1989;154:354-9.
7. Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 1982;215:413-15.
8. Corbett AD, Paterson SJ, McKnight AT, Magnan J, Kosterlitz HW. Dynorphin and dynorphin are ligands for the kappa-subtype of opiate receptor. Nature 1982;299:79-81.
9. Darke S, Hall W. Levels and correlates of polydrug use among heroin users and regular amphetamine users. Drug Alcohol Depend 1995;39:231-5.
10. Dum J, Blasig J, Herz A. Buprenorphrine: demonstration of physical dependence liability. Eur J Pharmacol 1981;70:293-300.
11. Eder H, Fischer G, Gombas W, Jagsch R, Stuhlinger G, Kasper S. Comparison of buprenorphine and methadone maintenance in opiate addicts. Eur Addict Res 1998;4 (Suppl 1):3-7.
12. Emrich HM, Dose M, Wolf R. The action of mood-stabilizers in affective disorders: an integrative view as a challenge. Neuropsychobiology 1993;27:158-62.
13. Emrich HM, Vogt P, Herz A. Possible antidepressive effects of opioids: action of buprenorphine. Ann NY Acad Sci 1982;398:108-12.
14. Fudala PJ, Jaffe JH, Dax EM, Johnson RE. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990;47:525-34.
15. Garcia-Borreguero D, Bronisch T, Apelt S, Yassouridis A, Emrich HM. Treatment of benzodiazepine withdrawal symptoms with carbamazepine. Eur Arch Psychiatry Clin Neurosci 1991;241:145-50.
16. Gossop M. The development of a Short Opiate Withdrawal Scale (SOWS). Addict Behav 1990;15:487-90.
17. Halikas JA, Crosby RD, Pearson VL, Graves NM. A randomized double-blind study of carbamazepine in the treatment of cocaine abuse. Clin Pharmacol Ther 1997;62:89-105.
18. Hall SM, Loeb PC, Kushner M. Methadone dose decreases and anxiety reduction. Addict Behav 1984;9:11-19.
19. Hautzinger M, Bailer M, Worall H, Keller F. Beck-Depressions-Inventar (BDI). Translated and adapted by Verlag Hans Huber. Bern: Verlag Hans Huber; 1994
20. Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 1979;17:81-110.
21. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990;9:811-18.
22. Iribarne C, Picart D, Dreano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 1997;60:1953-64.
23. Janke W, Debus G. Die Eigenschaftswörterliste (EWL-K) - Ein Verfahren zur Erfassung der Befindlichkeit. Göttingen: Hogrefe; 1978.
24. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978;35:501-16.
25. Johnson RE, Cone EJ, Henningfield JE, Fudala PJ. Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clin Pharmacol Ther 1989;46:335-43.
26. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992;267:2750-5.
27. Kanof PD, Aronson MJ, Ness R. Organic mood syndrome associated with detoxification from methadone maintenance. Am J Psychiatry 1993;150:423-8.
28. Kasvikis Y, Bradley B, Gossop M, Griffiths P, Marks I. Clonidine versus long- and short-term methadone-aided withdrawal from opiates. An uncontrolled comparison. Int J Addict 1990;25:1169-78.
29. Kerr BM, Thummel KE, Wurden CJ et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994;47:1969-79.
30. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992;13:177-84.
31. Kosten TR, Kleber HD. Buprenorphine detoxification from opioid dependence: a pilot study. Life Sci 1988;42:635-641.
32. Kosten TR, Morgan C, Kleber HD. Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse 1991;17:119-28.
33. Krantz MJ, Mehler PS. Treating opioid dependence. Growing implications for primary care. Arch Intern Med 2004;164:277-88.
34. Kuhlman JJJ, Lalani S, Magluilo JJ, Levine B, Darwin WD. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996;20:369-78.
35. Kuhlman JJJ, Levine B, Johnson RE, Fudala PJ, Cone EJ. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998;93:549-59.
36. Latowsky M. Improving detoxification outcomes from methadone maintenance treatment: the interrelationship of affective states and protracted withdrawal. J Psychoact Drugs 1996;28:251-7.
37. Law FD, Bailey JE, Allen DS, et al. The feasibility of abrupt methadone-buprenorphine transfer in British opiate addicts in an outpatient setting. Addict Biol 1997;2:191-200.
38. Leander JD. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 1987;26:1445-7.
39. Levin FR, Fischman MW, Connerney I, Foltin RW. A protocol to switch high-dose, methadone-maintained subjects to buprenorphine. Am J Addict 1997;6:105-16.
40. Ling W, Wesson DR. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend 2003;70:S49-57.
41. Malcolm R, Ballenger JC, Sturgis ET, Anton R. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry 1989;146:617-21.
42. Märkl A. Rauschgiftlage 1996. In: Jahrbuch Sucht 1998. Hüllinghorst R, Merfert-Diete C, Lindemann F, editors. Neuland Verlag: Geesthacht; 1997, pp. 67-82.
43. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine- like drugs in the non-dependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976;197:517-32.
44. Mattick RP, Hall W. Are detoxification programmes effective? Lancet 1996;347:97-100.
45. McCarthy PS, Howlett GJ. Physical dependence induced by opiate partial agonists in the rat. Neuropeptides 1984;5:11-14.
46. Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. Science 1980;207:657-9.
47. Okuma T, Inanaga K, Otsuki S et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology (Berl) 1979;66:211-17.
48. Paetzold W, Eronat V, Seifert J, Holze I, Emrich HM, Schneider U. [Detoxification of poly-substance abusers with buprenorphine. Effects on affect, anxiety, and withdrawal symptoms]. Nervenarzt 2000;71:722-9.
49. Petitjean S, Stohler R, Deglon JJ et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 2001;62:97-104.
50. Pini LA, Sternieri E, Ferretti C. Dapiprazole compared with clonidine and a placebo in detoxification of opiate addicts. Int J Clin Pharmacol Res 1991;11:99-105.
51. Placidi GF, Lenzi A, Lazzerini F, Cassano GB, Akiskal HS. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 1986;47:490-4.
52. Poser W, Poser S. Medikament - Missbrauch und Abhängigkeit. Stuttgart: Thieme; 1996.
53. Post RM, Weiss SRB. Kindling Implications for the course and treatment of affective disorders. In: Anticonvulsants in. Modigh K, Roback OH, Vestergaard P, editors. Petersfield: Wrightson Biomedical Publishing Ltd; 1994, pp. 113-37.
54. Schneider U, Paetzold W, Eronat V et al. Buprenorphine and carbamazepine as a treatment for detoxification of opiate addicts with multiple drug misuse: a pilot study. Addict Biol 2000;5:65-9.
55. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry 1991;48:448-52.
56. Seifert J, Metzner C, Paetzold W et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone. Pharmacopsychiatry 2002;35:159-64.
57. Senay EC. Methadone maintenance treatment. Int J Addict 1985;20:803-21.
58. Seow SS, Quigley AJ, Ilett KF et al. Buprenorphine: a new maintenance opiate? Med J Aust 1986;144:407-11.
59. Soars MG, Petullo DM, Eckstein JA, Kasper SC, Wrighton SA. An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 2004;32:140-8.
60. Strain EC, Preston KL, Liebson IA, Bigelow GE. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 1992;261:985-93.
61. Uehlinger C, Deglon J, Livoti S, Petitjean S, Waldvogel D, Ladewig D. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss multicentre study. Eur Addict Res 1998;4 (Suppl 1):13-18.
62. Umehara K, Shimokawa Y, Miyamoto G. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Biol Pharm Bull 2002;25:682-5.
63. Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl) 1995;119:268-76.
64. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet 1999;353:221-6.
65. Wiesbeck GA, Schuckit MA, Kalmijn JA, Tipp JE, Bucholz KK, Smith TL. An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction 1996;91:1469-78.
66. Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos 2003;31:768-72.